Lessons from the front lines of value-based care:

The OCM's impact on community oncology

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Nearly three years after its introduction, the CMS’s Oncology Care Model (OCM) remains the most ambitious and far-reaching initiative to shift cancer care toward value-based models.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Charles Saunders
Chief executive officer, Integra Connect
Table of Contents

YOU MAY BE INTERESTED IN

 For nearly 30 years, the American Cancer Society’s prostate cancer screening guidelines have advised men to discuss prostate-specific antigen, or PSA, testing with a clinician and weigh potential benefits and harms, rather than treat screening as an unquestioned routine. This “informed decision-making” recommendation was consistent with guidelines from all major professional organizations in the United States, Canada, and Europe. 
For patients with an HPV-related form of throat cancer, treatment is often highly effective, with cure rates as high as 90%, depending on the disease stage. Now, researchers are investigating whether some patients can safely avoid additional treatment while maintaining excellent cancer outcomes.
Charles Saunders
Chief executive officer, Integra Connect

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login